Smart ECM
RESAvecEvento 493986 / Edizione 1

4Th international florence symposium from genes to target therapy in hematology

4° Simposio Internazionale di Firenze su ematologia (Firenze, 12-13/11/2026). Sessioni su leucemie acute e croniche, mieloma multiplo, linfomi, MPN, MDS e terapie targeted con KOL internazionali. 12 crediti ECM.

Provider
AvecAvec (2299)
Crediti ECM
12
Costo
Gratuito
Durata
12 ore
Date
12 - 13 novembre 2026

Razionale scientifico

Hematology is a continuously changing discipline virtuously standing half the way between the bench and the bed. It is continuously informed by advancements in genetics and pathophysiology that, at a sometimes incredible pace, translate into diagnostic, prognostic and therapeutic benefits for the patients. This fourth edition of the Florence Symposium "From genes to targeted therapy in hematology" will host international KOL presenting the latest news in oncologic and non-oncologic hematologic diseases with the aim to boost knowledge and interactions among participants.

Luogo

Palazzo della Borsa della Camera di Commercio
Piazza Mentana, 1-2, Firenze (FI)

Programma

Giovedì 12 Novembre 2026· Palazzo della Borsa della Camera di Commercio, Firenze
  • 13:30-13:40Welcome and IntroductionAlessandro Maria Vannucchi
  • 13:40-14:00NPM1-AML: novel understanding and novel therapiesCristina Papayannidis
  • 14:00-14:20The era of lower-intensity and targeted regimens: who is really unfit?Naseema Gangat
  • 14:20-14:30Panel discussion
  • 14:30-15:00Maintenance therapy in acute myeloid leukemia: from historical controversy to precision strategyGail J. Roboz, Francesco Mannelli
  • 15:00-15:30Long term efficacy and survivorship in CAR-T cell therapyAnnalisa Ruggeri, Chiara Nozzoli
  • 15:30-16:00Translating clinical trial evidence into daily practice in CLL treatmentOthman Al-Sawaf, Alessandro Sanna
  • 16:00-16:20Coffee break
  • 16:20-16:40New treatment paradigm for newly diagnosed elderly patientsAlessandra Larocca
  • 16:40-17:00Anti-BCMA therapies in R/R MM (relapsed/refractory multiple myeloma)Xavier Leleu
  • 17:00-17:10Panel discussion
  • 17:10-17:40MRD-directed therapy for multiple myelomaCirino Botta, Elisabetta Antonioli
  • 17:40-18:00Target therapy of immune thrombocytopeniaFrancesco Zaja
  • 18:00-18:20Inflammation, Thrombosis and cancer: where's the link?Tiziano Barbui
  • 18:20-18:40Regulation of Hepcidin metabolism: challenges and opportunitiesDomenico Girelli
  • 18:40-18:50Panel discussion
  • 18:50-19:20Shedding light on clonal cytopenias and related diseasesLuca Malcovati, Valeria Santini
Venerdì 13 Novembre 2026· Palazzo della Borsa della Camera di Commercio, Firenze
  • 08:30-08:50Are JAK inhibitors all the same for myelofibrosis?Francesco Passamonti
  • 08:50-09:10Interferon for MPN: old story, new avenuesJean Jacques Kiladjian
  • 09:10-09:30Approved and novel therapies for systemic mastocytosisJason Gotlib
  • 09:30-09:40Panel discussion
  • 09:40-10:10Allogeneic transplant: adapting to targeted and MRD-guided treatment paradigmsCharles Craddock, Massimo Martino
  • 10:10-10:30After first line therapy in Hodgkin diseasesAnna Sureda
  • 10:30-10:50Bispecifics and CAR-T in follicular lymphoma: current and future directionsMartin Hutchings
  • 10:50-11:10Current and evolving therapeutic approaches for DLBCLMartin Hutchings
  • 11:10-11:20Panel discussion
  • 11:20-11:40Coffee break
  • 11:40-12:10Implementing transplantation strategies for myelofibrosisNicolaus Kröger, Paola Guglielmelli
  • 12:10-12:40MDS/MPN: what's behind a name? (Special Lecture)Ayalew Tefferi, Alessandro Maria Vannucchi
  • 12:40-13:10Selected oral communications
  • 13:10-13:40Lunch
  • 13:40-14:10Selected oral communications
  • 14:10-14:30APL (acute promyelocytic leukemia): lessons still to learnMaria Teresa Voso
  • 14:30-14:50Molecular Insights for Targeted Therapy in T-ALL/LBLRoberta La Starza
  • 14:50-15:00Panel discussion
  • 15:00-15:30From log of molecular response to TFR in CML: did we get it?Massimo Breccia, Fabrizio Pane
  • 15:30-15:50Coffee break
  • 15:50-16:10Risk-adapted therapy in MDS (Myelodysplastic syndromes)Matteo Giovanni Della Porta
  • 16:10-16:30Novel therapies for hemophiliaFlora Peyvandi
  • 16:30-16:50Gene therapy for hemoglobinopathiesDavid Rees
  • 16:50-17:10Molecular mechanisms of Richter TransformationDimitar Efremov
  • 17:10-17:20Closure of the meetingAlessandro Maria Vannucchi

Responsabili del corso

AVEC

Provider

ID Provider: N° 2299

Città: Cologno Monzese (MI)

Tipologia: Società, Agenzie Ed Enti Privati

Stato accreditamento: Standard - 1° Rinnovo

  • Alessandro Maria Vannucchi

    Responsabile scientifico

    Specializzazione: Professore di Ematologia, Università di Firenze

Relatori e docenti

  • Othman Al-sawaf

    Relatore

  • Elisabetta Antonioli

    Moderatore

  • Luca Arcaini

    Moderatore

  • Tiziano Barbui

    Relatore

  • Monica Bocchia

    Moderatore

Domande frequenti

L'evento è accreditato per: Medico Chirurgo (Oncologia, Genetica Medica, Medicina Interna, Laboratorio Di Genetica Medica, Medicina Trasfusionale, Ematologia, Anatomia Patologica).

Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.

Sei un provider ECM?

Contattaci per scoprire come possiamo collaborare.

Contattaci